please find enclosed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech Limited reported Q3 FY26 standalone revenue of ₹1,336.60 lakhs, up 9.4% YoY from ₹1,221.25 lakhs, while 9-month revenue grew 12.9% to ₹3,880.12 lakhs. Standalone Q3 PAT rose 40.7% YoY to ₹125.83 lakhs (Q3 FY25: ₹89.43 lakhs), but 9-month PAT fell 45.2% to ₹350.08 lakhs, largely because 9M FY25 had an unusually high 'other income' of ₹465.18 lakhs versus just ₹41.04 lakhs in 9M FY26. Consolidated numbers were similar, with Q3 PAT of ₹124.81 lakhs (+52% YoY) and 9M PAT of ₹345.38 lakhs. Total expenses rose on higher employee costs, depreciation, and traded-goods purchases, while finance costs declined. The statutory auditor, P. Murali & Co., issued an unqualified review report with no qualifications or emphasis-of-matter paragraphs.
Quarterly performance is healthy with strong PAT growth on the operating side, but the year-on-year 9-month PAT decline looks worse than it really is due to a one-off other-income spike last year. Underlying operations appear stable, though margins have clearly compressed compared with the prior year.